Sugi Predict

Sugi Predict / Compounds / SCHEMBL3758446

SCHEMBL3758446

SCHEMBL3758446

CC(C)(C)OC(=O)NCCCNC(=O)c1ccc(N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESRRG P62508 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ SLC22A2 O15244 1/20 0.50
▸ SLC22A1 O15245 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ ACHE P22303 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ EPHX2 P34913 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ PMP22 Q01453 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ CA1 P00915 5/20 0.48
▸ CA2 P00918 5/20 0.48
▸ CA12 O43570 4/20 0.48
▸ CA9 Q16790 4/20 0.48
▸ HDAC3 O15379 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC1 Q13547 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29780267 0.97 ESRRG (0.53) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL3904926 0.96 TDP1 (0.55) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL22939550 0.96 TDP1 (0.55) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL750337 0.94 ESRRG (0.56) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL14158944 0.93 ALDH1A1 (0.57) ALDH1A1LMNAMAPK1TDP1CA1
SCHEMBL23832608 0.92 ALDH1A1 (0.52) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL3523655 0.90 TDP1 (0.60) ALDH1A1MAPK1TDP1CA1CA2
SCHEMBL21163666 0.89 ESRRG (0.51) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL22939679 0.88 SMN1; SMN2 (0.52) ESRRGALDH1A1LMNASLC22A2SLC22A1
SCHEMBL22939676 0.88 SMN1; SMN2 (0.52) ESRRGALDH1A1LMNASLC22A2SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624038-B2 Molecules and methods related to treatment of uncontrolled cellular proliferation ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) 2026-05-12 — — US disclosed
US-20220251097-A1 MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION ST. JUDE CHILDREN'S RESEARCH HOSPITAL 2022-08-11 — — US disclosed
WO-2021022076-A1 MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2021-02-04 — — WO disclosed
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 — — EP disclosed
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 — — EP disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 — — US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 — — US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 — — US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 — — US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 — — US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 — — US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 — — US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 — — US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 — — US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 — — WO disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251097-A1 MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION MKI67, BCL2, PCNA ESRRG 1684/4885ALDH1A1 2500/4885LMNA 1215/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ESRRG 2633/4885ALDH1A1 1403/4885LMNA 4581/4885
US-12624038-B2 Molecules and methods related to treatment of uncontrolled cellular proliferation CCNC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MKI67 ESRRG 3141/4885ALDH1A1 972/4885LMNA 204/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ESRRG 2633/4885ALDH1A1 1403/4885LMNA 4581/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ESRRG 2005/4885ALDH1A1 1431/4885LMNA 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.